NASHVILLE, Tenn.--(BUSINESS WIRE)--The Mental Health Marketing Conference (MHM) is excited to announce the launch of its innovative online learning platform, MHM365, on August 1, 2024. Created to meet ...
The Phase 2 study in patients with C9orf72-related ALS/FTD was a multi-center, randomized, double-blind, placebo-controlled parallel-group, two-arm study with an open-label treatment period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback